2026-01-10 - Analysis Report
Okay, here's a comprehensive analysis of Hims & Hers Health Inc. (HIMS), based on the data provided.

**0. Preliminary Data Summary**

*   **HIMS Return:** 117.13%
*   **S&P 500 (VOO) Return:** 71.38%
*   **Current Price:** $33.87
*   **Last Market Price:** $31.69

**1. Return Rate vs. S&P 500 (VOO) & Company Overview**

*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company that provides personalized healthcare products and services direct to consumers.
*   **Cumulative Return (HIMS):** 117.13%
*   **Cumulative Return (VOO):** 71.38%
*   **Divergence:** 44.6 (Relative Divergence: 31.4)
*   **Analysis:** HIMS has significantly outperformed the S&P 500 over the observed period.  The divergence of 44.6 indicates a substantial difference in returns. The relative divergence of 31.4 suggests this outperformance is not at the high end of its historical range compared to the S&P500, indicating a moderate degree of outperformance relative to its past.

**Alpha, Beta Analysis**

|            | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
| :--------- | :----- | :----- | :----- | :--- | :----- |
| 2020-2022  | -19.0% | 67.1% | -17.0% | 0.7  | 1.4    |
| 2021-2023  | -65.0% | 67.1% | -66.0% | 1.6  | 1.9    |
| 2022-2024  | 119.0% | 42.0% | 99.0% | 1.7  | 5.2    |
| 2023-2025  | 114.0% | 57.5% | 52.0% | 2.1  | 6.9    |

*   **CAGR:** Wide fluctuations in the compounded growth rate are showing the volatile nature of the company with a transition from negative to high positive growth rates.
*   **MDD:** High MDD values point to significant drawdowns, especially in the earlier periods, implying considerable risk. The decrease in MDD in 2022-2024 could show increased stability.
*   **Alpha:** Alpha is an indication of performance of stock compared to benchmark index. The alpha in later period indicates good performance of the stock compared to the benchmark index
*   **Beta:** Beta is a measure of a stock's volatility in relation to the market. A beta greater than 1 suggests HIMS is more volatile than the S&P 500, which is supported by the high values. The general upward trend suggests volatility is increasing.
*   **Cap(B):** It demonstrates the expansion in market capitalization, from $1.4 billion to $6.9 billion.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** $33.87
*   **Last Market Price:** $31.69 (-6.44% change, Previous Close: $33.87)
*   **5-day SMA:** 34.58
*   **20-day SMA:** 35.13
*   **60-day SMA:** 40.16

*   **Analysis:** The price is below all moving averages, indicating a short-term downward trend.  The last market price drop of -6.44% is a significant decrease and warrants attention.

**3. RSI, PPO, Market Risk Indicator, and Expected Return**

*   **MRI:** 0.7 (Medium Investment)
*   **RSI:** 43.65 (Neutral)
*   **PPO:** 0.62 (Slightly bullish)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (3 shares - Safe - MRI:0.80)
*   **Recent Relative Divergence Change:** -1.7 (Short-term decline)
*   **Expected Return:** 45.6% (Long-term, vs. S&P 500)

*   **Analysis:** The MRI suggests a medium level of investment risk. The RSI is in a neutral zone, not indicating overbought or oversold conditions. The PPO is slightly positive, indicating a slight bullish momentum. The negative divergence change suggests a recent short-term pullback.  The high expected return indicates potential for long-term growth exceeding the S&P 500.

**4. Recent News & Significant Events**

*   **Negative Headlines:** Several headlines from January 8, 2026, are negative, including a price target cut by BofA, a significant price plunge over the past three months, and questions about the company's growth prospects.
*   **Mixed Headlines:** Other headlines are more balanced, discussing Hims & Hers' growth story, expansion beyond GLP-1s, and potential upside.
*   **Analysis:** The news sentiment is mixed, but the presence of negative headlines, especially regarding price targets and recent performance, is a cause for concern. These news articles likely contributed to the recent price decline.

**4-2. Analyst Opinions**

*   **Consensus:** Hold (Mean: 2.93)
*   **Target Price:** Average: $43.50, High: $85.00, Low: $25.00
*   **Analysis:** The consensus rating is "Hold," suggesting analysts are generally neutral on the stock. The wide range in target prices reflects uncertainty about the company's future performance. The recent rating changes, if any were present, were not available in the data.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출        |
| :--------- | :----- | :---------- |
| 2025-11-03 | 0.07   | 0.60 B$     |
| 2025-08-04 | 0.19   | 0.54 B$     |
| 2025-05-05 | 0.22   | 0.59 B$     |
| 2024-11-04 | 0.35   | 0.40 B$     |
| 2025-11-03 | 0.35   | 0.40 B$     |

*   **Analysis:** Earnings per share (EPS) and revenue figures show fluctuation across the given quarters. While revenue has generally increased, EPS shows more volatility. The most recent quarter shows a significant drop in EPS, which is concerning.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| :----------- | :--------- | :-------------- |
| 2025-09-30   | $0.60B     | 73.80%         |
| 2025-06-30   | $0.54B     | 76.39%         |
| 2025-03-31   | $0.59B     | 73.50%         |
| 2024-12-31   | $0.48B     | 76.81%         |
| 2024-09-30   | $0.40B     | 79.16%         |

**Capital and Profitability:**

| Quarter      | Equity     | ROE   |
| :----------- | :--------- | :---- |
| 2025-09-30   | $0.58B     | 2.72% |
| 2025-06-30   | $0.56B     | 7.55% |
| 2025-03-31   | $0.55B     | 9.01% |
| 2024-12-31   | $0.48B     | 5.46% |
| 2024-09-30   | $0.44B     | 17.18% |

*   **Revenue & Profitability Analysis:** Revenue has generally increased, demonstrating growth. Profit margins have remained relatively high, indicating strong pricing power and efficient operations. However, there's a slight downward trend in profit margins over the most recent quarters.
*   **Capital & Profitability Analysis:** Equity has increased, indicating growing net assets.  However, Return on Equity (ROE) has decreased significantly, especially in the most recent quarter, suggesting a decline in profitability relative to shareholder equity.

**7. Comprehensive Analysis (Summary)**

Hims & Hers Health Inc. (HIMS) is a volatile stock with the potential for high returns but also carries significant risk.

*   **Strengths:**
    *   Significant outperformance of the S&P 500 over the analyzed period.
    *   Strong revenue growth and high-profit margins.
    *   High expected return relative to the S&P 500, suggesting potential for long-term growth.
*   **Weaknesses/Risks:**
    *   Recent negative price action and concerning news headlines (price target cuts, price plunge).
    *   High volatility (as indicated by Beta and MDD).
    *   Decreasing EPS and ROE in recent quarters.
    *   "Hold" consensus rating with a wide range of analyst price targets reflecting uncertainty.
    *   The stock's price is below its moving averages, suggesting a short-term downward trend.
*   **Overall:** HIMS presents a high-risk, high-reward investment opportunity. The company has shown strong growth potential but also faces challenges regarding profitability and investor sentiment. The recent negative news and price action should be carefully considered. An investment decision should depend on your risk tolerance and investment horizon. Further due diligence and monitoring of the company's performance are crucial.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.